

Radboud university medical center

Obstetrics and Gynecology

P.O. Box 9101, 6500 HB Nijmegen

The Netherlands

Internal postal code 791

Geert Grooteplein Zuid 10

Route 791

Head of Department

Prof. Dr. A. Nap

www.radboudumc.nl

Dutch Chamber of Commerce

trade register 41055629/4

September 10th 2023

Motivation letter

Dear Madam/sir,

I am happy to write this motivation letter for the application to be nominated for the **ESGO Council 2024–2028**. As gynecologic oncologist I am working at the Radboud university medical center Nijmegen (NL).

As past chair of the ENITEC network (2019-2022), I have learned the importance of European connections-collaborations to improve healthcare for women with gynecological cancers. Gynecological cancers are relatively rare when compared to many other cancers, hence coordination within ESGO will enhance our knowledge by trials and international guidelines in the aim to achieve comparable quality of care among all European women with gynecological cancer.

In my daily work I am active on all domains that are envisioned by the ESGO: *Prevention, Research, Excellence in care and Education*. My research is focused on translational and personalized endometrial cancer. Interestingly, as part of this research I am actively involved in projects to implement healthy lifestyle as part of routine cancer care in order to improve sustainable life style changes. As about 60% of all cancers are related to modifiable risk factors, lifestyle will be highly relevant in future healthcare, underlined by increasing health care costs. In the last decades technical innovations have improved the understanding of cancer behavior resulting in personalized treatment options. Yet, for an actual personalized approach better understanding of patients' perspectives is crucial to achieve these goals. Since two years I am chair of the medical advisory board of OLIJF, Dutch patient advocacy group of female cancer. In this position I have learned that perspectives of women with cancer, often differ from us as health care providers, with more focus on *quality of life* and proper balance with *quantity of life*. This may be challenging for ministries of health who often focus on survival benefit as ultimate goal. ESGO can contribute to these national and international discussions with focus on well-being of women with gynecological cancers.

I am looking forward to contribute to these future challenges with support of my application by the chair of the Dutch working party Gyn-Onc (Brigitte Slangen) and the chair of the Gyn-Onc DGOG (Christianne Lok).

Please find my CV attached, and do not hesitate to contact me if there are any questions.

Yours sincerely,



Johanna (Hanny) M.A. Pijnenborg, MD, PhD, associate Professor
Radboud university medical center, Nijmegen, The Netherlands

 +31-653781696 /  Hanny.MA.Pijnenborg@radboudumc.nl



Curriculum vitae

Personal Data

Surname: Pijnenborg
Name: Johanna Maria Antoinetta (Hanny)
Date of Birth: 30-10-1969
Nationality: Dutch
Mobile number: +31-653781696
E-mail work: Hanny.MA.Pijnenborg@radboudumc.nl



Education

2009-2011 Fellow-ship gynecologic oncology

- Radboud university medical center, Nijmegen, The Netherlands
- BC Cancer Agency, Vancouver BC, Canada

2001-2003 GROW Research Institute, Maastricht University Medical Center, Maastricht, The Netherlands
1997 - 2004 Training Obstetrics & Gynecology, Maastricht & Veldhoven, The Netherlands
1988 - 1996 Medicine, University of Maastricht, The Netherlands

PhD

2-12-2005 "The Predictive value of molecular markers for recurrent endometrial carcinoma".

Job

2016 - current Gynecologic Oncologist, Radboud university medical center Nijmegen, The Netherlands

- June 2022, appointed Associate Professor
- July 2023, appointed Research Group leader endometrial cancer

2011 - 2016 Gynecologic oncologist, Gynecological Oncology Center South
2004 - 2008 General gynecologist, TweeSteden hospital, Tilburg, The Netherlands

Special expertise

gynecologic oncology / minimal invasive (Certified Robotic) surgery / pathology

Management

- 2020-current, adjunct theme leader Women's Cancers, Radboudumc, Nijmegen
- 2020-current, chair medical advisory board OLIJF (*Dutch Patient advocacy group female cancer*)
- 2019-current, board member DGOG, gynecologic oncology group
- 2019-2022 chair ENITEC consortium
- 2017-2019 chair-elect of ENITEC consortium

Memberships

- Dutch Society for Obstetrics and Gynecology (NVOG)
- Dutch Gynecological Oncology Group (DGOG)
- European Society for Gynecological Endoscopy (ESGE)
- European Society for Gynecological Oncology (ESGO)
- European Network of Individualized Treatment in Endometrial Cancer (ENITEC)
- American Association of Cancer Research (AACR)

Research 2016-2023

- Co-supervised 8 PhD candidates, and 5 PhDs ongoing
- Opponent of public PhD defense national and internationally
- 2.082 K € Research grants

Awards and Prizes

- 2019 and 2017 Nominated twice by ENITEC network for ESGO Helga Salvesen Award
- 2019 Nominated as PhD supervisor of the year, RIHS, Nijmegen
- 2018 Nominated as best teacher of the year, Radboudumc, Nijmegen
- 2016 Nominated as best teacher of the year, Residents Utrecht

Publications

Over 150 international peer reviewed publications

- <https://scholar.google.nl/citations?user=sH-g5ekAAAAJ&hl=nl>
- <https://www.researchgate.net/profile/Johanna-Pijnenborg>

Teaching activities - Presentations

Involved in many teaching activities, national guidelines and presented at national and international meetings

- 2022 and 2017, 1th author of chapter “uterine malignancies” in Textbook of Obstetrics & Gynecology.
- May 2021 Webinar OLIJF, focus on endometrial cancer <https://www.youtube.com/watch?v=0ci1Xk2lcA0>
- 2016 - current tutor WOG, annual Gynecological Oncology Course, and “State of the art, endometrial carcinoma”, Maastricht, The Netherlands.
- 2010 - 2017 tutor “Gynecological Oncology anatomy”, PAOG Heyendaal, Nijmegen

A handwritten signature in black ink, consisting of several overlapping loops and a long horizontal stroke extending to the right.

Nijmegen, 10-9-2023